Effect of an inactivated vaccine against SARS-CoV-2


  • Dawn O'Shea
  • Univadis Medical News
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Researchers in China have published interim results from ongoing randomised, double-blind, placebo-controlled, phase 1 and 2 trials assessing an inactivated COVID-19 vaccine. The interim analysis was conducted on June 16 and updated on July 27.

In the phase 2 trial, 224 (aged 18-59 years) healthy participants were randomised to 5 μg/dose of the vaccine in two schedules; vaccine injections on days 0 and 14 (n=84) vs aluminium hydroxide (alum) only (n=28), and days 0 and 21 (n=84) vs alum only (n=28).

Adverse reactions (ARs) occurred in five (6.0%) and four (14.3%) participants in the first schedule group, and 16 (19.0%) and five (17.9%) receiving the second schedule group.

The most common ARs were injection site pain and fever, which were mild and self-limiting. No serious ARs were noted.

The geometric mean titres of neutralising antibodies were 121 (95% CI 95-154) and 247 (95% CI 176-345) at day 14 after injections on days 0 and 14 and on days 0 and 21, respectively. There were no detectable antibody responses in alum-only groups.

The findings demonstrate immunogenicity and suggest the inactivated vaccine is associated with a low rate of ARs.

. Phase 3 trials will be needed to confirm these findings.